Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Titel:
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Auteur:
Bellmunt, Joaquim Maroto, Pablo Bonfill, Teresa Vazquez, Federico Perez-Gracia, Jose Luis Juanpere, Nuria Hernandez-Prat, Anna Hernandez-Llodra, Silvia Rovira, Ana Juan, Oscar Rodriguez-Vida, Alejo